ROPES grant

 

Title: 

Roles of epitranscriptomic in diseases

Acronym:

ROPES 

Duration: 

01 December 2020 - 30 November 2024 

Total budget:

3 095 829 EUR 

IIMCB budget: 

227 478 EUR 

Supervisor at IIMCB:    

Janusz M. Bujnicki, WP1 Leader 

Project website: 

https://r1.unitn.it/ropes/ 

 

Emerging evidence indicates that like chromatin, mRNA carries certain covalent modifications. Although their role is still being investigated, it seems that these modifications determine the levels, translatability and subcellular compartmentalisation of target mRNAs with profound consequences for cell processes. The EU-funded ROPES project is focusing on epitranscriptomics as the missing link between genomic variability and cellular phenotype. Results will help delineate disease mechanisms, identify novel biomarkers and develop innovative therapies. By training Early-Stage Researchers (ESRs), ROPES aims to establish a European framework that can accelerate research efforts and industrial applications in the promising field of epitranscriptomics. 

One of the selected ESRs is trained by prof. Janusz M. Bujnicki, head of Laboratory of Bioinformatics and Protein Engineering at IIMCB. Andrea Campanini is exposed to research and innovation activities through the supervision of a European top-class network of researchers, comprehensive training, retreat programmes and research secondments planned in the group of Prof. Quattrone (UNITN) and Prof. Frye (DKFZ). 

The ROPES project involves ten European laboratories and one biotech company from nine different countries, including: 
     1. University of Trento, (Italy), Leader
     2. Medical University of Wien (Austria),
     3. University of Lausanne (Switzerland),
     4. International Institute of Molecular and Cell Biology (Poland),
     5. Umea University (Sweden),
     6. German Cancer Research Center DKFZ (Germany),
     7. il Consiglio Nazionale delle Ricerche (Italy),
     8. Centre for Genomic Regulation (Spain),
     9. CEITEC- University of Masaryk (Czech Republic),
     10. Immagina Biotechnology Srl (Italy),
     11. Free University of Bruxelles (Belgium).
  

News: